ClinicalTrials.gg
Active, not recruitingNCT04060927Updated Oct 29, 2026Results posted

Pilot Study of SGRT Alone vs. SGRT With Fiducials for Breath Hold SBRT tx of the Lung

An interventional study of SGRT in Lung Cancer, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.

Enrollment
17th of 31
45 · median 46
Started
2019
with 5 others
No phase
14 of 36
3 open now
Registered
28th of 36
by date

Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one is the 17th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2019, is one of 14 with no phase, and was the 28th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This is a pilot study designed to to provide data and experience comparing two different techniques of breath hold SBRT treatments. The first technique will include SGRT, but with the assistance of implanted fiducials. Subjects will be treated with a breath hold technique utilizing SGRT, but will also be imaged during treatment with fiducial match. The second technique will utilize SGRT for breath hold treatments without the assistance of implanted fiducials/continuous imaging.

Read the detailed description

The study's primary objective is estimate the incidence of SBRT and fiducial-related pulmonary toxicities for subjects treated with SBRT who have tumors that move ≥ 1 cm in 3 different cohorts: 1) free breathing with SGRT 2) breath hold utilizing SGRT only; 3) breath hold utilizing SGRT in combination with implanted fiducials. Secondary objectives also include Estimate reliability of gated SBRT treatments utilizing SGRT vs. SGRT with fiducials estimating local control for SBRT in subjects treated in the three different cohorts, estimating overall survival, and evaluating quality of life. A safety objective of estimating acute and long-term grade 2 or higher non-hematologic toxicities attributed to SBRT/fiducial implantation in subjects treated in the three different cohorts will also be explored.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • NSCLC
  • Lung
  • Radiation Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject must meet all of the following applicable inclusion criteria to participate in this study:

  1. Written with HIPAA authorization for release of personal health information.
  2. Age ≥18 years at the time of consent. Because no dosing or adverse event data are currently available on the use of fiducials in combination with SBRT in subjects \<18 years of age, children are excluded from this study.
  3. Performance Status of ≤ 2.
  4. Stage IA-IIB (T1a-T3bN0) presumed non-small cell lung cancer, carcinoid tumors, or lung that have ≥ 1 cm of respiratory associated motion measured on 4DCT at time of simulation for SBRT with or without respiratory motion suppression techniques. Histologic confirmation of is encouraged but not required. Primary or metastatic tumor ≤ 7 cm.
  5. Subjects may be receiving systemic chemotherapy or other systemic agents prior to enrollment, but these agents must be stopped during SBRT treatments.
  6. Females of (FCBP) must have a negative serum pregnancy test within 14 days prior to day 1 of treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are (at least 12 consecutive months with no menses without an alternative medical cause).
  7. The effects of radiation on the developing human fetus are not well described. For this reason, women of child-bearing potential and non-sterilized men who are sexually active with a woman of child-bearing potential must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of \<1% per year when used consistently and correctly) from the time of informed consent until 5 days after last dose of SBRT. Contraceptive methods with low user dependency are preferable but not required.
  8. As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the criteria below may not participate in the study:

  1. Prior radiation to the chest that would overlap with the current radiation fields and determined by the treating physician to impede the treatment of the study .
  2. Active ongoing pulmonary infection or pneumonitis that is requiring active treatment with antibiotics or . Prior pneumonitis from drug or other therapies that has been treated within 15 days of first day of treatment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Group 1

    Freebreathing SBRT with SGRT

    Device: SGRT

  • Experimental
    Group 2

    Breath hold SBRT with SGRT

    Device: SGRT

  • Experimental
    Group 3

    Breath hold SBRT with SGRT in combination with implanted fiducials

    Device: SGRT

Interventions

  • DeviceSGRT

    Surface Guided Radiation Therapy

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 2 or Higher SBRT-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0

    A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.

    Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment

  2. Number of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0

    A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.

    Time frame: from date of fiducial placement to 12 months after completion of SBRT treatment

Secondary outcomes

  1. Reliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Directional Shifts

    Measured shift deltas for each of the directional (in cm; vertical, longitudinal, lateral) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in centimeters for each directional shift, as well as a calculated vector composite of the directional shifts. Reliability was measured with each fraction.

    Time frame: from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days

  2. Reliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Rotational Shifts

    Measured shift deltas for each of the rotational (in degrees; roll, pitch, rotation) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in degrees for each rotational shift. Reliability was measured with each fraction.

    Time frame: from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days

  3. Local Control of Treated Tumor(s)

    The outcome will be measured as the duration of time from enrollment to progression of the subject's treated tumor(s)

    Time frame: up to 24 months

  4. Overall Survival

    This outcome will be measured as the duration of time from the date of enrollment to the study to the date of death from any cause.

    Time frame: approx. 2 years

  5. Change From Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference Score

    The MDASI-LC Module includes 22 questions to assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning. Scores for each item range from 0 to 10, where 0 indicates no symptoms and 10 indicates worst possible symptoms. Arithmetic mean of the items completed was calculated to determine a mean total symptom + interference score ranging from 0 to 10. The mean score is reported if more than 50% of the items are completed on a given administration. Change from baseline was calculated as the post baseline timepoint mean score minus the baseline mean score for each participant. As higher scores indicate worse symptoms and more interference at a given timepoint, if the change from baseline is a positive value, this indicates a worsening of symptoms at the post-baseline timepoint.

    Time frame: From pre-SBRT to 1, 3, 6, and 12 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)

Other outcomes

  1. Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to SBRT as Assessed by NCI CTCAE v.5.0

    A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.

    Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)

  2. Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0

    A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.

    Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)

  3. SBRT Administration - Number of Fractions Received

    Descriptive summary of SBRT administration. Number of fractions of SBRT the participant received on study.

    Time frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days

  4. SBRT Administration - Total Dose Delivered

    Descriptive summary of SBRT administration. Total dose (in Gray) of SBRT received.

    Time frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days

  5. Pulmonary Function Test (PFT) Results at Baseline and 6 Months

    Results from the PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity of the lungs for carbon monoxide (DLCO), were captured as a percentage of the predicted normal values based on age, height, gender, and sex. FVC measures the total lung volume and capacity. FEV1 measures the speed of airflow. DLCO measures how well gases transfer from inside of lungs into bloodstream. PFTs were done pre-SBRT and 6 months after the last treatment of SBRT.

    Time frame: pre-SBRT and 6 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)

07

Results

Posted Oct 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3
Started15255
Completed000
Not completed15255
Withdrew: Death11110
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject010
Withdrew: Still on study4124

Outcome measures

PrimaryNumber of Participants With Grade 2 or Higher SBRT-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0

A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.

Time frame:
from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 or Higher SBRT-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0
ParticipantsGroup 1Group 2Group 3
Number of Participants With Grade 2 or Higher SBRT-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0110
Statistical analysis
  • Group 1 · Rate: 0.0667 · 95% CI 0.0017 to 0.3195Confidence interval estimated using the Clopper Pearson method
  • Group 2 · Rate: 0.04 · 95% CI 0.001 to 0.2035Confidence interval estimated using the Clopper Pearson method
  • Group 3 · Rate: 0.0 · 95% CI 0.0 to 0.5218Confidence interval estimated using the Clopper Pearson method
PrimaryNumber of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0

A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher pulmonary adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.

Time frame:
from date of fiducial placement to 12 months after completion of SBRT treatment
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0
ParticipantsGroup 3
Number of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.00
Statistical analysis
  • Group 3 · Rate: 0.0 · 95% CI 0.0 to 0.5218Confidence interval estimated using the Clopper Pearson method
SecondaryReliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Directional Shifts

Measured shift deltas for each of the directional (in cm; vertical, longitudinal, lateral) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in centimeters for each directional shift, as well as a calculated vector composite of the directional shifts. Reliability was measured with each fraction.

Time frame:
from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
Reported as:
Least squares mean · cm
Reliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Directional Shifts
cmGroup 2Group 3
Vertical0.09 ± 0.020.10 ± 0.04
Longitudinal0.16 ± 0.020.19 ± 0.06
Lateral0.08 ± 0.020.08 ± 0.04
Vector composite0.23 ± 0.030.24 ± 0.08
SecondaryReliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Rotational Shifts

Measured shift deltas for each of the rotational (in degrees; roll, pitch, rotation) shifts were determined utilizing surface guided radiation therapy (SGRT, or SGRT + fiducials) based on target position at the time of verification imaging using cone beam computed tomography. This was recorded as numerical values in degrees for each rotational shift. Reliability was measured with each fraction.

Time frame:
from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
Reported as:
Least squares mean · degrees
Reliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Rotational Shifts
degreesGroup 2Group 3
Roll0.20 ± 0.070.10 ± 0.17
Pitch0.18 ± 0.060.17 ± 0.15
Rotation0.08 ± 0.050.32 ± 0.13
SecondaryLocal Control of Treated Tumor(s)

The outcome will be measured as the duration of time from enrollment to progression of the subject's treated tumor(s)

Time frame:
up to 24 months

Results for this outcome have not been posted.

SecondaryOverall Survival

This outcome will be measured as the duration of time from the date of enrollment to the study to the date of death from any cause.

Time frame:
approx. 2 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference Score

The MDASI-LC Module includes 22 questions to assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning. Scores for each item range from 0 to 10, where 0 indicates no symptoms and 10 indicates worst possible symptoms. Arithmetic mean of the items completed was calculated to determine a mean total symptom + interference score ranging from 0 to 10. The mean score is reported if more than 50% of the items are completed on a given administration. Change from baseline was calculated as the post baseline timepoint mean score minus the baseline mean score for each participant. As higher scores indicate worse symptoms and more interference at a given timepoint, if the change from baseline is a positive value, this indicates a worsening of symptoms at the post-baseline timepoint.

Time frame:
From pre-SBRT to 1, 3, 6, and 12 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
Reported as:
Least squares mean · score on a scale
Change From Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference Score
score on a scaleGroup 1Group 2Group 3
Change from baseline to 1 month after SBRT-0.70 ± 0.33-0.06 ± 0.260.83 ± 0.55
Change from baseline to 3 months after SBRT-0.38 ± 0.34-0.25 ± 0.280.78 ± 0.55
Change from baseline to 6 months after SBRT-0.74 ± 0.36-0.22 ± 0.280.17 ± 0.55
Change from baseline to 12 months after SBRT-0.80 ± 0.420.01 ± 0.290.68 ± 0.59
Other pre-specifiedNumber of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to SBRT as Assessed by NCI CTCAE v.5.0

A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to SBRT.

Time frame:
from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to SBRT as Assessed by NCI CTCAE v.5.0
ParticipantsGroup 1Group 2Group 3
Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to SBRT as Assessed by NCI CTCAE v.5.0130
Other pre-specifiedNumber of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0

A binary variable was determined for each participant indicating whether the participant experienced at least one grade 2 or higher non-hematologic adverse event (according to NCI Common Terminology for Adverse Events version 5.0) during treatment or within 12 months after completion of SBRT that was determined to be related (possibly, probably, or definitely attributed) to implantation of fiducials.

Time frame:
from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
Reported as:
Count of participants · Participants
Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0
ParticipantsGroup 3
Number of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.00
Other pre-specifiedSBRT Administration - Number of Fractions Received

Descriptive summary of SBRT administration. Number of fractions of SBRT the participant received on study.

Time frame:
From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
Reported as:
Count of participants · Participants
SBRT Administration - Number of Fractions Received
ParticipantsGroup 1Group 2Group 3
1 fraction received010
3 fractions received13235
5 fractions received210
Other pre-specifiedSBRT Administration - Total Dose Delivered

Descriptive summary of SBRT administration. Total dose (in Gray) of SBRT received.

Time frame:
From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
Reported as:
Median · Gray
SBRT Administration - Total Dose Delivered
GrayGroup 1Group 2Group 3
SBRT Administration - Total Dose Delivered54 (50 to 55)54 (18 to 60)54 (54 to 54)
Other pre-specifiedPulmonary Function Test (PFT) Results at Baseline and 6 Months

Results from the PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and diffusing capacity of the lungs for carbon monoxide (DLCO), were captured as a percentage of the predicted normal values based on age, height, gender, and sex. FVC measures the total lung volume and capacity. FEV1 measures the speed of airflow. DLCO measures how well gases transfer from inside of lungs into bloodstream. PFTs were done pre-SBRT and 6 months after the last treatment of SBRT.

Time frame:
pre-SBRT and 6 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
Reported as:
Median · % of predicted normal values
Pulmonary Function Test (PFT) Results at Baseline and 6 Months
% of predicted normal valuesGroup 1Group 2Group 3
FVC % at baseline82 (42 to 132)94 (55 to 127)84 (49 to 100)
FVC % at 6 months after SBRT80 (64 to 90)95 (59 to 124)78 (61 to 111)
FEV1 % at baseline79 (18 to 102)75 (37 to 130)64 (36 to 71)
FEV1 % at 6 months after SBRT69 (51 to 88)84.5 (39 to 125)60 (42 to 79)
DLCO % at baseline54 (19 to 78)68 (28 to 118)51 (44 to 70)
DLCO % at 6 months after SBRT53 (30 to 76)67 (27 to 102)68 (34 to 84)

Adverse events

Collected over From enrollment or fiducial implantation, during treatment, until 12 months after last treatment of SBRT (on average SBRT treatment lasted 4.8 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 111/15 (73.3%)2/15 (13.3%)1/15 (6.7%)
Group 211/25 (44%)1/25 (4%)3/25 (12%)
Group 30/5 (0%)0/5 (0%)0/5 (0%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2Group 3
Lung infectionInfections and infestations1/150/250/5
Respiratory, thoracic and mediastinal disorders - OtherRespiratory, thoracic and mediastinal disorders1/150/250/5
Aortic injuryInjury, poisoning and procedural complications0/151/250/5
Most frequent other events
Most frequent other events
EventGroup 1Group 2Group 3
FatigueGeneral disorders and administration site conditions1/151/250/5
Non-cardiac chest painGeneral disorders and administration site conditions1/150/250/5
PneumonitisRespiratory, thoracic and mediastinal disorders1/151/250/5
Dermatitis radiationInjury, poisoning and procedural complications0/151/250/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group 1Group 2Group 3Total
<=18 years0000
Between 18 and 65 years1225
>=65 years1423340
Age, Continuous
Age, Continuous(years)Group 1Group 2Group 3Total
Median77 (54 to 89)76 (34 to 86)70 (56 to 72)76 (34 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Total
Female78419
Male817126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1Group 2Group 3Total
Hispanic or Latino0000
Not Hispanic or Latino1524544
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1Group 2Group 3Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2103
White1322540
More than one race0101
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Group 3Total
United States1525545
Baseline MDASI-LC Total Symptom and Interference Score
Baseline MDASI-LC Total Symptom and Interference Score(score on a scale)Group 1Group 2Group 3Total
Mean2.0 ± 1.51.9 ± 1.32.7 ± 1.82.0 ± 1.4
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Oct 2025, 72 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 72 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 19, 2019
StartActual
Sep 25, 2019
Primary completionActual
Oct 18, 2025
CompletionEst.
Oct 2026
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedIncidenceNumber of Participants With Grade 2 or Higher SBRT and fiducial-related pulmonary toxicitiesPulmonary Toxicities as assessedAssessed by NCI CTCAE v.5.0Time frame: 12 months → from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment
  • AddedNumber of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0Time frame: from date of fiducial placement to 12 months after completion of SBRT treatment
Oct 29, 2026
Documents
Secondary outcomes
4 edited, 1 time frame changed, 5 added
What changed in the outcomes
  • EditedReliability of gatedGated SBRT treatments utilizingTreatments Utilizing SGRT vs. SGRT with fiducialsWith Fiducials - Directional ShiftsTime frame: approx. 2 weeks → from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
  • EditedLocal controlControl of treated tumorTreated Tumor(s)Time frame: up to 24 months
  • EditedChange fromFrom Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference ScoreTime frame: pre-SBRT and 1, 3, 6, and 12 months after the last treatment of SBRT → From pre-SBRT to 1, 3, 6, and 12 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
  • AddedReliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Rotational ShiftsTime frame: from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
  • Time frameOverall Survivalapprox. 5 years → approx. 2 years
  • Editedother outcomeIncidenceNumber of Participants With Grade 2 or higher nonHigher Non-hematologic toxicities attributedToxicities Attributed to SBRT and fiducial implantationas Assessed by NCI CTCAE v.5.0Time frame: up to 12 months after the last treatment of SBRT → from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
  • Addedother outcomeNumber of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
  • Addedother outcomeSBRT Administration - Number of Fractions ReceivedTime frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
  • Addedother outcomeSBRT Administration - Total Dose DeliveredTime frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
  • Addedother outcomePulmonary Function Test (PFT) Results at Baseline and 6 MonthsTime frame: pre-SBRT and 6 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedIncidenceNumber of Participants With Grade 2 or Higher SBRT and fiducial-related pulmonary toxicitiesPulmonary Toxicities as assessedAssessed by NCI CTCAE v.5.0Time frame: 12 months → from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment
    • AddedNumber of Participants With Grade 2 or Higher Fiducial-related Pulmonary Toxicities as Assessed by NCI CTCAE v.5.0Time frame: from date of fiducial placement to 12 months after completion of SBRT treatment
    Secondary outcomes 4 edited, 1 time frame changed, 5 added
    What changed in the outcomes
    • EditedReliability of gatedGated SBRT treatments utilizingTreatments Utilizing SGRT vs. SGRT with fiducialsWith Fiducials - Directional ShiftsTime frame: approx. 2 weeks → from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
    • EditedLocal controlControl of treated tumorTreated Tumor(s)Time frame: up to 24 months
    • EditedChange fromFrom Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference ScoreTime frame: pre-SBRT and 1, 3, 6, and 12 months after the last treatment of SBRT → From pre-SBRT to 1, 3, 6, and 12 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)
    • AddedReliability of Gated SBRT Treatments Utilizing SGRT vs. SGRT With Fiducials - Rotational ShiftsTime frame: from start of SBRT treatment to completion of SBRT treatment, median duration was 4 days
    • Time frameOverall Survivalapprox. 5 years → approx. 2 years
    • Editedother outcomeIncidenceNumber of Participants With Grade 2 or higher nonHigher Non-hematologic toxicities attributedToxicities Attributed to SBRT and fiducial implantationas Assessed by NCI CTCAE v.5.0Time frame: up to 12 months after the last treatment of SBRT → from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
    • Addedother outcomeNumber of Participants With Grade 2 or Higher Non-hematologic Toxicities Attributed to Fiducial Implantation as Assessed by NCI CTCAE v.5.0Time frame: from date of SBRT start or fiducial placement to 12 months after completion of SBRT treatment (on average SBRT treatment lasted 4.8 days)
    • Addedother outcomeSBRT Administration - Number of Fractions ReceivedTime frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
    • Addedother outcomeSBRT Administration - Total Dose DeliveredTime frame: From enrollment to completion of SBRT treatment; SBRT treatment lasted on average 4.8 days
    • Addedother outcomePulmonary Function Test (PFT) Results at Baseline and 6 MonthsTime frame: pre-SBRT and 6 months after the last treatment of SBRT (on average SBRT treatment lasted 4.8 days)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04060927
Collaborators
Atrium Health Levine Cancer Institute
Responsible party
Sponsor
First posted
Aug 19, 2019
Start date
Sep 25, 2019
Primary completion
Oct 18, 2025
Completion
Oct 2026 (estimated)
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

John Heinzerling, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion